ChemoCentryx Inc (NASDAQ:CCXI) CFO Susan M. Kanaya sold 850 shares of the business’s stock in a transaction on Tuesday, June 26th. The shares were sold at an average price of $13.25, for a total value of $11,262.50. Following the completion of the transaction, the chief financial officer now owns 38,985 shares of the company’s stock, valued at $516,551.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of ChemoCentryx traded up $0.86, hitting $13.98, during trading on Thursday, according to Marketbeat.com. 579,400 shares of the company traded hands, compared to its average volume of 303,570. ChemoCentryx Inc has a 1 year low of $5.42 and a 1 year high of $15.08. The stock has a market capitalization of $641.41 million, a PE ratio of 38.83 and a beta of 1.66. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.18.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The company had revenue of $9.55 million for the quarter, compared to analysts’ expectations of $9.10 million. equities research analysts expect that ChemoCentryx Inc will post -1 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wasatch Advisors Inc. grew its stake in shares of ChemoCentryx by 9.2% during the 1st quarter. Wasatch Advisors Inc. now owns 2,382,932 shares of the biopharmaceutical company’s stock valued at $32,408,000 after buying an additional 201,044 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of ChemoCentryx during the 1st quarter valued at $12,920,000. Carmignac Gestion purchased a new stake in shares of ChemoCentryx during the 1st quarter valued at $5,305,000. Millennium Management LLC grew its stake in shares of ChemoCentryx by 26.7% during the 1st quarter. Millennium Management LLC now owns 324,112 shares of the biopharmaceutical company’s stock valued at $4,408,000 after buying an additional 68,281 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of ChemoCentryx by 21.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 267,066 shares of the biopharmaceutical company’s stock valued at $1,589,000 after buying an additional 46,626 shares during the period. 50.08% of the stock is owned by institutional investors.
Several brokerages have weighed in on CCXI. Raymond James began coverage on ChemoCentryx in a report on Thursday. They issued a “strong-buy” rating and a $18.00 price target for the company. ValuEngine upgraded ChemoCentryx from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a report on Thursday, March 15th. BidaskClub upgraded ChemoCentryx from a “sell” rating to a “hold” rating in a report on Wednesday, May 16th. Finally, Cowen reiterated a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 10th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $16.80.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.